enGene (NASDAQ:ENGN) Earns Overweight Rating from Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of enGene (NASDAQ:ENGN) in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $26.00 price target on the stock.

Several other research firms also recently issued reports on ENGN. Raymond James initiated coverage on shares of enGene in a report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. HC Wainwright initiated coverage on shares of enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of enGene in a report on Monday, December 23rd. Finally, UBS Group downgraded shares of enGene from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $34.00 to $7.00 in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, enGene presently has an average rating of “Buy” and an average price target of $25.89.

enGene Stock Performance

ENGN stock opened at $6.15 on Tuesday. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $271.71 million, a price-to-earnings ratio of -10.59 and a beta of -0.65. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The firm has a 50 day moving average of $6.77 and a two-hundred day moving average of $7.21.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, equities analysts anticipate that enGene will post -1.57 EPS for the current fiscal year.

Institutional Trading of enGene

A number of hedge funds have recently bought and sold shares of the stock. Fcpm Iii Services B.V. boosted its holdings in enGene by 11.0% in the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock valued at $64,057,000 after purchasing an additional 954,610 shares during the period. VR Adviser LLC raised its stake in shares of enGene by 41.5% in the 4th quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock valued at $33,559,000 after buying an additional 1,480,573 shares in the last quarter. Deep Track Capital LP raised its stake in shares of enGene by 74.8% in the 4th quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock valued at $30,308,000 after buying an additional 1,949,942 shares in the last quarter. Blue Owl Capital Holdings LP raised its stake in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock valued at $21,014,000 after buying an additional 101,006 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of enGene by 84.7% in the 4th quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock valued at $8,145,000 after buying an additional 561,797 shares in the last quarter. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.